Vimian Group ABVIMGF 76 PB Ratio is 1.76 as of Jun. 26, 2026, which is 32% below its 10-year median of 2.60. GuruFocus rates VIMGF with a GF Score™ of 76/100 and a GF Value™ of $3.24. The stock has 2 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Vimian Group AB ranks worse than 50.51% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Vimian Group AB's share price is $2.77. Vimian Group AB's Book Value per Share for the quarter that ended in Mar. 2026 was $1.57. Hence, Vimian Group AB's PB Ratio of today is 1.76.
The historical rank and industry rank for Vimian Group AB's PB Ratio or its related term are showing as below:
VIMGF'
s PB Ratio Range Over the Past 10 Years
Min: 1.5 Med: 2.6 Max: 13.41
Current: 2.02
During the past 9 years, Vimian Group AB's highest PB Ratio was 13.41. The lowest was 1.50. And the median was 2.60.
VIMGF's PB Ratio is ranked worse than 50.51% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs VIMGF: 2.02
During the past 12 months, Vimian Group AB's average Book Value Per Share Growth Rate was 1.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -19.20% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Vimian Group AB was 3442.50% per year. The lowest was -48.00% per year. And the median was 6.70% per year.
Back to Basics: PB Ratio
Vimian Group AB (OTCPK:VIMGF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vimian Group AB PB Ratio Related Terms
Vimian Group AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Vimian Group AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Vimian Group AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vimian Group AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vimian Group AB (VIMGF) has a PB Ratio of 1.76 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vimian Group AB and its competitors. This is 32% below median its historical median of 2.60. Over the past decade, Vimian Group AB's PB Ratio has ranged from 1.50 to 13.41. According to the industry distribution chart, Vimian Group AB ranks #99 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 50.5%.
Is Vimian Group AB's PB Ratio too high?
Vimian Group AB's current PB Ratio of 1.76 is 32% below median its 10-year median of 2.60. Over the past 10 years, this metric has ranged from a low of 1.50 to a high of 13.41. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Vimian Group AB's value of 1.76 is 14.1% below this industry median. Based on the distribution chart, Vimian Group AB ranks #99 out of 196 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Vimian Group AB has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #99 out of 196 companies for PB Ratio. This places Vimian Group AB in the lower half of its industry. The industry median PB Ratio is 2.05. Vimian Group AB's value of 1.76 is 14.1% below this benchmark. Historically, Vimian Group AB's own PB Ratio has ranged from 1.50 to 13.41 over the past decade. While the company's 10-year median is 2.60 vs. the industry median of 2.05, Vimian Group AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current PB Ratio of 1.76 is 14.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vimian Group AB and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current PB Ratio is 1.76, which is 32% below median its own 10-year median of 2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current PB Ratio of 1.76. The stock's GF Value™ is $3.24, compared to a current price of $2.77 — trading 14.5% below its estimated fair value. The current PB Ratio is 1.76, which is 32% below median its 10-year median of 2.60 and 14.1% below the Medical Diagnostics & Research industry median of 2.05. Vimian Group AB's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current PB Ratio is 1.76 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 14.5% below its estimated GF Value™ of $3.24.
Key valuation signals for VIMGF:
PB Ratio: 1.76 (32% below median its 10-year median of 2.60)
GF Value™: $3.24 vs. price of $2.77 (14.5% below fair value)
Industry Position: 14.1% below the Medical Diagnostics & Research median (#99 of 196)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
76GF Score
Get the complete analysis for VIMGF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
